Deutsche Gesellschaft für Schmerzmedizin (DGS)

This sponsor has funded 9 studies across 1 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
12247 Finalised EFFICACY, TOLERABILITY AND SAFETY OF AN ORAL ENZYME COMBINATION VS. DICLOFENAC IN OSTEOARTHRITIS OF THE KNEE – RESULTS OF AN INDIVIDUAL PATIENT-LEVEL... No No
22093 Finalised Practice survey tumor pain No No
31322 Finalised NON-INTERVENTIONAL RETROSPECTIVE EVALUATION OF TOLERABILITY AND EFFICACY OF THE ATYPICAL WHO-STEP III OPIOIDANALGESIC TAPENTADOL PR UNDER REAL-WORLD... No No
31328 Finalised CANCER PAIN AND TREATMENT CHARACTERISTICS in GERMANY – A CROSS_SECTIONAL ONLINE PATIENT SURVEY (CANPAIN) No No
32754 Finalised NON-INTERVENTIONAL RETROSPECTIVE EVALUATION OF TOLERABILITY AND EFFICACY OF TYPICAL ORAL LONG-ACTING WHO-STEP III OPIOID ANALGESICs UNDER REAL-WORLD... No No
38332 Finalised A real world evidence study from Germany on the safety and efficacy of tapentadol and typical oral long-acting opioid analgesics in chronic low back... No No
44365 Finalised Biopsychosocial characteristics of patients with fibromyalgia / chronic widespread pain. A cross-sectional review of depersonalized data from the... No No
49718 Finalised Pridinol vs. nsaids - efficacy/tolerability in acute (low) back pain. A propensity-score matched, comparative 2-cohort, 4-week real world evidence... No No
50135 Finalised Bio-psycho-social characteristics of patients with migraine. A cross-sectional review of depersonalized data from the German Pain e-Registry. (BIOMIC) No No

PAS by Risk Management Plan (RMP) requirement

Deutsche Gesellschaft für Schmerzmedizin (DGS)

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.